Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:12 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Personalization of Long-Term Antiplatelet Therapy - RAPID EXTEND
NCT03729401 · Ottawa Heart Institute Research Corporation · PHASE4 · terminated · last registry update 2026-05-06 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Testing supplies unavailable.” | – | Registry record, Ottawa Heart Institute Research Corporation |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against P2RY12 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-22Also stopped (terminated): Odense University Hospital, Short duration of aspirin and prasugrel + Conventional duration of aspirin and prasugrel (NCT06718179)
- 2026-10-21Phase 3 first posted: Khyber Medical University Peshawar, Thalidomide + Danazol (NCT07884773)
- 2026-09-25Also stopped (suspended): Fondation Ophtalmologique Adolphe de Rothschild, Cangrelor (NCT04667078)
- 2026-09-14Phase 3 first posted: First Affiliated Hospital of Fujian Medical University, Tirofiban+Oral Dual Antiplatelet Therapy + Dual Antiplatelet Therapy plus Normal Saline (NCT07818083)
- 2026-08-20Phase 3 first posted: The First Affiliated Hospital of Anhui Medical University, Recombinant Human Prourokinase for Injection (rhPro-UK) (NCT07776873)
- 2026-08-05Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Rivaroxaban, or Edoxaban , or Apixaban , or Dabigatran + Aspirin (NCT07746882)
- 2026-07-30Also stopped (terminated): University Hospital, Bordeaux, Paracetamol concentration time curve from 0 to 120 min (NCT02251249)
- 2026-07-07Phase 3 first posted: Children's Hospital of Fudan University, IVIG + Aspirin (NCT07686770)
- 2026-07-06Also stopped (terminated): Marissa Jarosinski, Ticagrelor 90mg (NCT04007055)
- 2026-06-24Also stopped (terminated): Alexion Pharmaceuticals, Inc., placebo + PRT060128 Potassium (NCT00546260)
- 2026-06-22Also stopped (terminated): University Hospital, Bordeaux, Ticagrelor alone + Combination lysine acetylsalicylate - clopidogrel (NCT02817789)
- 2026-06-09Results posted on the registry: W.L.Gore & Associates, Thienopyridine (clopidogrel or prasugrel) (NCT04100135)
- 2026-06-09Also stopped (terminated): W.L.Gore & Associates, Thienopyridine (clopidogrel or prasugrel) (NCT04100135)
- 2026-06-05Phase 3 first posted: Columbia University, Prasugrel 5mg (NCT07629635)
- 2026-05-14Results posted on the registry: University of Texas Southwestern Medical Center, Polypill + Usual Care (individual medications prescribed by primary cardiologist) (NCT05514938)
- 2026-05-14Results posted on the registry: Brigham and Women's Hospital, dual anti-platelet therapy + Placebo (NCT05567562)
- 2026-05-13Phase 3 first posted: Cardiocentro Ticino, Clopidogrel + Ticagrelor (NCT07582835)
- 2026-05-07Phase 3 first posted: Khalid F Alhabib, Aspirin + Clopidgrel 75 mg daily (NCT07572747)
- 2026-04-06Phase 3 first posted: Fondation Hôpital Saint-Joseph, Clopidogrel 75 mg/day (NCT07512960)
- 2026-03-17Phase 3 first posted: First Hospital of China Medical University, Tenecteplase (0.25mg/kg) + Standard Medical Management (NCT07476898)
- 2026-03-12Phase 3 first posted: Population Health Research Institute, Rivaroxaban + ASA (NCT07468448)
- 2026-03-06Phase 3 first posted: Sunnybrook Health Sciences Centre, Edoxaban 15 mg + Aspirin or clopidogrel (NCT07454707)
- 2026-02-13Results posted on the registry: Marissa Jarosinski, Ticagrelor 90mg (NCT04007055)
- 2026-02-06Results posted on the registry: Lumosa Therapeutics Co., Ltd., LT3001 drug product + Placebo (NCT04809818)
- 2026-01-30Phase 3 first posted: Weifang Medical University, Tirofiban + dual antiplatelet therapy (NCT07379190)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision